PlantForm secures $2M in equity financing

Atlantic Assets Trust Limited of Edinburgh, Scotland has signed an agreement to invest a total of $2 million in PlantForm to support manufacturing process scale up and other activities required to complete Phase 1 clinical trials for the company’s first biosimilar drug candidate, a plant-produced version of the breast cancer drug Herceptin® (trastuzumab).

The funding will enable PlantForm to produce the antibody drug in the quantities required for Phase 1 clinical trials, and to perform the necessary characterization and analysis of the drug.

Atlantic Assets Trust Limited is managed by Scott Investment Partners LLP, which is based in Henley-on-Thames, U.K. The agreement gives Atlantic Assets Trust a 20 per cent equity position in PlantForm.

“This investment recognizes the value of PlantForm’s biologic drug program,” said Dr. Don Stewart, PlantForm President and CEO. “It allows the company to take a major step forward as we bring a low-cost version of this important breast cancer drug to market. We’re very pleased and look forward to further demonstrating the capabilities of our technology.”

“PlantForm’s technology is truly groundbreaking and will play a major role in the future of low-cost pharmaceutical biologics,” said Dr. Oliver Mahony, Director of Atlantic Assets Trust Limited. “We are privileged to partner with PlantForm and we are looking forward to growing with them over the coming years.”

See more

New funding expands HIV antibody program

The National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) is providing technical advisory services as well as a financial contribution of up to $477,679 to PlantForm for the second phase of the company’s human immunodeficiency virus (HIV) antibody development project.

PlantForm is focusing on producing antibodies that fight HIV infection by disrupting the virus’s method of entry into human CD4+ lymphocytes (T-cells).

The new funding will enable the company to develop an additional three antibodies for production in plants (bringing the total number of antibodies developed to six), with the goal of developing an anti-HIV therapeutic cocktail. This phase of the project, which runs until February 2015, also includes testing a selection of the antibodies and developing a stable transgenic plant host for antibody production.

Funding for the project is provided through NRC-IRAP’s Canadian HIV Technology Development (CHTD) Program, which is part of the Canadian HIV Vaccine Initiative (CHVI), a collaboration between the Government of Canada and the Bill & Melinda Gates Foundation. The CHTD program awarded PlantForm $389,891 for the first phase of the project.

See more

Mind to Market award finalist

PlantForm has been named a finalist for the Ontario Centres of Excellence (OCE) Mind to Market Award 2013. The winner of the award — for outstanding research collaboration and commercialization — will be announced at the OCE AGM Oct. 29.

Join us online!

Follow PlantForm on Twitter, LinkedIn and Facebook for regular updates on our activities and industry news:
                          Facebook page - PlantForm

September 2013

First U.S. patent for PlantForm technology

PlantForm’s plant-produced antidote to cobra toxin has been issued a U.S. patent.

“This is the first issued patent for an antibody drug candidate produced using our plant-based manufacturing technology,” said Dr. Don Stewart, President and CEO. “It is a tangible asset that adds value to the company, and it demonstrates the capability of our platform technology, which has tremendous potential to produce a broad range of antibody and protein drugs and vaccines.”
Read more

Charting a path for plant-made vaccines

PlantForm is pleased to join the Canadian Society of Microbiologists and the OECD to sponsor the Plant-made Vaccines as an Alternative to Antibiotics: Countering Antibiotic Resistance and Ensuring Human Food Safety Workshop Sept. 23-25 in London, Ont.

Antibiotic resistance is a top global health concern, and plants are potential low-cost production systems for bacterial vaccines. PlantForm's Chief Scientific Officer, Dr. Chris Hall, will speak on Biotech commercialization: from concept to production at the workshop on Sept. 23.


Sept. 17
PlantForm’s AGM takes place at 11 a.m. at 120 Research Lane, Suite 200, Guelph, Ont. Shareholders please RSVP to
Sept. 22
Director Research Dr. Michael D. McLean is giving a talk on Biologics, Biosimilars and Biobetter Medicines at the 2013 Ontario Society of Medical Technologists conference in London, Ont.
Nov. 4-6
PlantForm will be at the international partnering conference BioEurope 2013 in Vienna, Austria.

Management Team

Don Stewart, PhD
President & CEO

David Cayea, BA
Chief Operating Officer

Ron Hosking, CA
Chief Financial Officer

J. Christopher Hall, PhD
Chief Scientific Officer

PlantForm is a Canadian company focused on providing
low-cost therapeutic antibody drugs that fight cancer and other critical illnesses.

Our mailing address is:
1920 Yonge St, Suite 200
Toronto, Ontario
For more information, contact:
Don Stewart
President & CEO